论文部分内容阅读
目的:探讨可溶性MICA(sMICA)在胆管癌患者外周血中的表达及其临床意义。方法:应用酶联免疫吸附试验法(ELISA)检测42例胆管癌患者的外周血sMICA的表达水平,分析其与临床病理特征的关系。结果:胆管癌患者血清sMICA水平显著高于正常对照组(P<0.01);胆管癌患者血清中sMICA的表达水平与血清中CA19-9水平、肿瘤浸润及淋巴结转移等临床病理特征密切相关(P<0.05);手术后胆管癌患者血清中sMICA水平明显下降。结论:胆管癌患者血清中sMICA水平明显增高,血清sMICA可作为胆管癌诊断的一种重要的指标。
Objective: To investigate the expression of soluble MICA (sMICA) in peripheral blood of patients with cholangiocarcinoma and its clinical significance. Methods: The expression of sMICA in peripheral blood of 42 patients with cholangiocarcinoma was detected by enzyme-linked immunosorbent assay (ELISA), and its relationship with clinicopathological features was analyzed. Results: Serum sMICA levels in patients with cholangiocarcinoma were significantly higher than those in normal controls (P <0.01). The serum levels of sMICA in patients with cholangiocarcinoma were significantly correlated with the serum levels of CA19-9, tumor invasion and lymph node metastasis <0.05). The level of sMICA in serum of patients with cholangiocarcinoma decreased significantly after operation. Conclusion: Serum sMICA levels in patients with cholangiocarcinoma were significantly increased, serum sMICA can be used as an important indicator of the diagnosis of cholangiocarcinoma.